Latest Ratings for ALLO
DateFirmActionFromTo Mar 2022Goldman SachsMaintainsNeutral Dec 2021RBC CapitalMaintainsOutperform Oct 2021JMP SecuritiesMaintainsMarket Outperform
View More Analyst...
Latest Ratings for ALLO
DateFirmActionFromTo Mar 2022Goldman SachsMaintainsNeutral Dec 2021RBC CapitalMaintainsOutperform Oct 2021JMP SecuritiesMaintainsMarket Outperform
View More Analyst...
Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Research analysts at Zacks Research issued their FY2026 earnings per share (EPS) estimates for Allogene Therapeutics in a research report...
HC Wainwright reaffirmed their buy rating on shares of Allogene Therapeutics (NASDAQ:ALLO Free Report) in a research note released on Tuesday morning, Benzinga reports. HC Wainwright...
Allogene Therapeutics (NASDAQ:ALLO Get Free Report)s stock had its buy rating reissued by stock analysts at HC Wainwright in a report issued on Tuesday, Benzinga reports...